

| | | | |
|--|---|------------------------|-------------------|
| Substitute for Form 1449 A & B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Application Number | 10/519,990 |
| | | Confirmation Number | 3209 |
| | | Filing Date | January 04, 2005 |
| | | First Named Inventor | Nicoletta BIANCHI |
| | | Art Unit | 1614 |
| | | Examiner Name | Not Yet Assigned |
| | | Attorney Docket Number | Q85654 |
| Sheet | 1 | of | |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document |
|--------------------|-----------------------|-----------------|--------------------------------------|--------------------------------|---|
| | | Number | Kind Code ² (if known) | | |
| | | US | | | |
| | | US | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Translation ⁶ |
|--------------------|-----------------------|---------------------------|---------------------|--------------------------------------|--------------------------------|---|--------------------------|
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | |
| | | | | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published. | Translation ⁶ |
|--------------------|-----------------------|--|--------------------------|
| SG | | G. RODGERS et al., "Novel Treatment Options in the Severe β -Globin Disorders", British Journal of Haematology, 91:263-268, 1995. | |
| | | J. ROCHETTE et al. "Fetal Hemoglobin Levels in Adults", Blood Reviews, 8:213-224, 1994. | |
| | | N. BIANCHI et al., "Accumulation of γ -globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine", British Journal of Haematology, 113(4): 951-961; 2001 | |
| | | DOVER et al, "Increased Fetal Hemoglobin in Patients Receiving Sodium 4-Phenylbutyrate", New England Journal of Medicine, 327:569-570, 1992. | |
| | | IKUTA et al. "Cellular and Molecular Effects of a Pulse Butyrate Regimen and New Inducers of Globin Expression and Hematopoiesis" Annals of New York Academy of Sciences, 850: 87-99, 1998 | |
| | | KAHAN, "Sirolimus: a comprehensive review" Expert Opinion. 2001 Nov; 2(11): 1903-1917 | |
| | | DICKMAN et al. "Antifungal Rapamycin Analogues with Reduced Immunosuppressive Activity", Bioorganic & Medicinal Chemistry Letters 10(2000) 1405-1408 | |
| | | DELL, "Antiproliferative Naphthopyrans: Biological Activity, Mechanistic Studies and Therapeutic Potential", Current Medicinal Chemistry, 1998, 5: 179-194 | |
| | | TRAUTMANN, et al. "Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis". Journal of Allergy Clinical Immunology, November 2001 839-846 | |
| | | REITAMO et al. "Efficacy of Sirolimus (rapamycin) administered concomitantly with a sub therapeutic dose of cyclosporine in the treatment of severe psoriasis: a randomized controlled trial" British Journal of Dermatology, 2001: 145: 438-445. | |
| | | GUBA et al. "Rapamycin inhibits primary and metastasis tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor" National Medical February 2002, Vol. 8, No. 2, 128-135 | |
| | | GARBER "Rapamycin's Resurrection: A new way to target the cancer cell cycle" National Cancer Institute, 2001, Vol. 93, No. 20, 1517-1519 | |
| | | BENITO et al. "Sirolimus (Rapamycin) for the treatment of refractory acute graft-versus-host disease", Transplantation, Vol. 72, No. 12, December 27, 2001, 1924-1929 | |
| | | RADOVANCEVIC et al. "Rapamycin reduces rejection in heart transplant recipients" Transplantation Proceedings, Vol. 33, 3321-3222, 2001 | |
| | | NISHIDA et al. "Sirolimus (Rapamycin)-Based Rescue Treatment following chronic rejection after liver transplantation" Transplantation Proceedings, 33: 1495 (2001) | |
| | | BIANCHI et al. "Induction of Erythroid Differentiation of Human K562 Cells by Cisplatin Analogs" Biochemical Pharmacology Vol. 60, 31-40, 2000 | |
| SG | | BIANCHI et al. "The DNA-binding drugs mithramycin and chromomycin are powerful inducers of erythroid differentiation of human K562 cells". British Journal of Haematology, 1999 104:258-265 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

| | | | |
|----|--|---|--|
| SG | | FIBACH, "Techniques for Studying Stimulation of Fetal Hemoglobin Production in Human Erythroid Cultures", Hemoglobin, 22(5&^), 445-458, 1998 | |
| | | FIBACH et al. "Hydroxyurea Increases Fetal Hemoglobin in Cultured Erythroid Cells Derived From Normal Individuals and Patients with Sickle Cell Anemia or β -Thalassemia" Blood, Vol. 81, No. 6 (March 15), 1993:1630-1963. | |
| | | HEID et al. "Real Time Quantitative PCR", Genome Research, 6:986-994, 1996 | |
| SG | | GIBSON et al. "A Novel Method for Real Time Quantitative RT-PCR", Genome Research, 6:995-1001, 1996 | |

| | | | |
|--------------------|--------------------------|-----------------|------------|
| Examiner Signature | /Satyanarayan Gudibande/ | Date Considered | 01/29/2007 |
|--------------------|--------------------------|-----------------|------------|



*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

10/519990

1

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.